These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 26762740)

  • 1. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines.
    Doi T; Ishikawa T; Okayama T; Oka K; Mizushima K; Yasuda T; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Naito Y; Itoh Y
    Oncol Rep; 2017 Mar; 37(3):1545-1554. PubMed ID: 28112370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
    Clavé S; Pijuan L; Casadevall D; Taus Á; Gimeno J; Hernández-Llodrà S; Rodríguez-Rivera M; Lorenzo M; Menéndez S; Albanell J; Espinet B; Arriola E; Salido M
    Histopathology; 2018 Jan; 72(2):259-269. PubMed ID: 28795418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
    Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.
    Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of inflammasomes in lung cancer cell lines and tissues.
    Kong H; Wang Y; Zeng X; Wang Z; Wang H; Xie W
    Tumour Biol; 2015 Sep; 36(10):7501-13. PubMed ID: 25910707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
    Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
    Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).
    Dworakowska D; Jassem E; Jassem J; Peters B; Dziadziuszko R; Zylicz M; Jakóbkiewicz-Banecka J; Kobierska-Gulida G; Szymanowska A; Skokowski J; Roessner A; Schneider-Stock R
    Lung Cancer; 2004 Mar; 43(3):285-95. PubMed ID: 15165086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
    Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
    Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.